We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Pfizer, Mylan Await Decision In Norvasc Patent Case

Law360 (December 7, 2006, 12:00 AM EST) -- After a seven-day bench trial, attorneys for Pfizer Inc. and generic drug maker Mylan Pharmaceuticals Inc. made closing arguments Wednesday, putting the final touch on a longstanding patent infringement suit over Pfizer’s blockbuster drug Norvasc.

Now that the trial before Judge Terrence F. McVerry of the U.S. District Court

Western District of Pennsylvania has wrapped up, both parties await a decision as to whether or not Mylan can sell a generic version of Norvasc.

Pfizer received Norvasc’s patent in 1987, and it is set to expire...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.